Impact of pronase on flow cytometric crossmatch outcome
Authors:
- Karl P. SchillingerKSKarl P. Schillinger
- Andrea A. ZacharyAZAndrea A. Zachary
- Annette M. JacksonAJAnnette M. Jackson
- 1 April 2011
- journal article
- Published by Elsevier in Human Immunology
- Vol. 72 (4) , 330-336
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord bloodHuman Immunology, 2009
- Using real data for a virtual crossmatchHuman Immunology, 2009
- Improved Graft Survival in Highly Sensitized Patients Undergoing Renal Transplantation After the Introduction of a Clinically Validated Flow Cytometry CrossmatchTransplantation, 2009
- Clinical Significance of a Positive Flow Crossmatch on the Outcomes of Cadaveric Renal TransplantsTransplantation Proceedings, 2008
- Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximabHuman Immunology, 2004
- Removal of CD20 with pronase: implications for flow crossmatch in patients with rituximabHuman Immunology, 2002
- IMPROVED FLOW CYTOMETRIC DETECTION OF HLA ALLOANTIBODIES USING PRONASETransplantation, 2001
- Hyperacute renal allograft rejection from anti-HLA class 1 antibody to B cells -antibody detection by two color FCXM was possible only after using pronase-digested donor lymphocytesTransplant International, 1997
- The use of pronase-digested human leukocytes to improve specificity of the flow cytometric crossmatchTransplant International, 1995
- IMPROVED GRAFT SURVIVAL FOR FLOW CYTOMETRY AND ANTIHUMAN GLOBULIN CROSSMATCH-NEGATIVE RETRANSPLANT RECIPIENTSTransplantation, 1990